Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other brokerages have also weighed in on RVNC. Guggenheim reaffirmed a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a report on Friday. Piper Sandler lowered shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 12th. Barclays reissued an “equal weight” rating and set a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Finally, William Blair reaffirmed a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $9.66.

Revance Therapeutics Trading Down 36.0 %

Shares of RVNC opened at $3.70 on Friday. The firm has a fifty day moving average price of $5.66 and a 200-day moving average price of $4.42. The firm has a market capitalization of $387.85 million, a P/E ratio of -1.92 and a beta of 0.95. Revance Therapeutics has a 12-month low of $2.30 and a 12-month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. Analysts predict that Revance Therapeutics will post -1.53 earnings per share for the current year.

Institutional Trading of Revance Therapeutics

Several hedge funds have recently modified their holdings of the company. Intech Investment Management LLC purchased a new position in shares of Revance Therapeutics in the 3rd quarter worth approximately $231,000. Alpine Associates Management Inc. purchased a new position in Revance Therapeutics in the third quarter worth $21,605,000. LMR Partners LLP acquired a new position in shares of Revance Therapeutics during the third quarter worth $11,648,000. Accredited Investors Inc. purchased a new stake in shares of Revance Therapeutics during the 3rd quarter valued at $67,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Revance Therapeutics during the 3rd quarter valued at $108,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.